Revisiting X-linked agammaglobulinemia
Journal of Human Immunity · 05.05.2025 · 1 (1)
DOI: 10.70962/jhi.20250020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Human Immunity, online erschienen am 28.04.2025. Verfasst von Hirokazu Kanegane und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.
Autor:innen und Institutionen
- Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Pediatrics, University of Washington, and Seattle Children's Research Institute, Seattle, WA, USA.
ORCID-Profile: Hirokazu Kanegane, Kay Tanita, Madoka Nishimura, Dan Tomomasa, Kento Inoue, Toru Kanamori, Akira Nishimura, Hans D Ochs
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
Zitieren
APA
Kanegane, H., Tanita, K., Nishimura, M., Tomomasa, D., Inoue, K., Kanamori, T., Nishimura, A., & Ochs, H. D. (2025). Revisiting X-linked agammaglobulinemia. Journal of Human Immunity, 1(1). https://doi.org/10.70962/jhi.20250020
Vancouver
Kanegane H, Tanita K, Nishimura M, Tomomasa D, Inoue K, Kanamori T, et al. Revisiting X-linked agammaglobulinemia. Journal of Human Immunity. 2025;1(1). doi:10.70962/jhi.20250020
BibTeX
@article{Kanegane2025,
author = {Kanegane, Hirokazu and Tanita, Kay and Nishimura, Madoka and Tomomasa, Dan and Inoue, Kento and Kanamori, Toru and Nishimura, Akira and Ochs, Hans D},
title = {Revisiting X-linked agammaglobulinemia},
journal = {Journal of Human Immunity},
year = {2025},
volume = {1},
number = {1},
doi = {10.70962/jhi.20250020}
}
EUVIMED